Mereo Biopharma

News

Ultragenyx, Mereo's brittle bone drug flames out in trials

Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives.

News

Rumour mill says AstraZeneca may be eyeing a takeover of Mer...

AstraZeneca is rumoured to be considering a bid to take control of its longstanding partner Mereo BioPharma, according to a

News

abstract shapes, bone structure, 3d render, bone

UK biotech Mereo gears up for key brittle bone drug data

UK biotech Mereo BioPharma is hoping the coming months will transform its fortunes as it prepares for potentially pivotal data for a brittle bone disease drug.

News

AZ licenses rare disease drug to Mereo BioPharma

Mereo Biopharma snaps up drug for AATD.

Ultragenyx, Mereo's brittle bone drug flames out in trials

Rumour mill says AstraZeneca may be eyeing a takeover of Mer...

UK biotech Mereo gears up for key brittle bone drug data

AZ licenses rare disease drug to Mereo BioPharma

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Mereo Biopharma

Editor's Picks